Cargando…

Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis

Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by a steatosis of the liver that may progress to more serious pathological conditions including: nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. As the prevalence of NAFLD has increased worldwide in recent years, path...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Dana L., Lakhani, Hari Vishal, Klug, Rebecca L., Snoad, Brian, El-Hamdani, Rawan, Shapiro, Joseph I., Sodhi, Komal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701750/
https://www.ncbi.nlm.nih.gov/pubmed/29177105
http://dx.doi.org/10.4172/2155-9899.1000523
_version_ 1783281399704322048
author Sharma, Dana L.
Lakhani, Hari Vishal
Klug, Rebecca L.
Snoad, Brian
El-Hamdani, Rawan
Shapiro, Joseph I.
Sodhi, Komal
author_facet Sharma, Dana L.
Lakhani, Hari Vishal
Klug, Rebecca L.
Snoad, Brian
El-Hamdani, Rawan
Shapiro, Joseph I.
Sodhi, Komal
author_sort Sharma, Dana L.
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by a steatosis of the liver that may progress to more serious pathological conditions including: nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. As the prevalence of NAFLD has increased worldwide in recent years, pathophysiology and risk factors associated with disease progression of NAFLD are at the focus of many studies. NAFLD is related to and shares common serum biomarkers with cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome (MetS). West Virginia (WV) is a state with some of the highest rates of CVD, obesity and diabetes mellitus. As NAFLD is closely related to these diseases, it is of particular interest in WV. Currently there is no cost-effective, standardized method used clinically to detect NAFLD prior to the onset of reversible complications. At this time, the diagnosis of NAFLD is made with costly radiologic studies and invasive biopsy. These studies are only diagnostic once changes to hepatic tissue have occurred. The diagnosis of NAFLD by traditional methods may not allow for successful intervention and may not be readily available in areas with already sparse medical resources. In this literature review, we identify a list of biomarkers common among CVD, T2DM, obesity, MetS and NAFLD. From this research we propose the following biomarkers are good candidates for inclusion in a panel of biomarkers for the early detection of NAFLD: adiponectin, AST, ALT, apo-B, CK18, CPS1, CRP, FABP-1, ferritin, GGT, GRP78, HDL-C, IGF-1, IL-1β, 6, 8, 10, IRS-2PAI-1, leptin, lumican, MDA SREBP-1c and TNF-α. Creating and implementing a biomarker panel for the early detection and attenuation of NAFLD, prior to the onset of irreversible complication would provide maximum benefit and decrease the disease burden on the patients and healthcare system of WV.
format Online
Article
Text
id pubmed-5701750
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-57017502017-11-24 Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis Sharma, Dana L. Lakhani, Hari Vishal Klug, Rebecca L. Snoad, Brian El-Hamdani, Rawan Shapiro, Joseph I. Sodhi, Komal J Clin Cell Immunol Article Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by a steatosis of the liver that may progress to more serious pathological conditions including: nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. As the prevalence of NAFLD has increased worldwide in recent years, pathophysiology and risk factors associated with disease progression of NAFLD are at the focus of many studies. NAFLD is related to and shares common serum biomarkers with cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome (MetS). West Virginia (WV) is a state with some of the highest rates of CVD, obesity and diabetes mellitus. As NAFLD is closely related to these diseases, it is of particular interest in WV. Currently there is no cost-effective, standardized method used clinically to detect NAFLD prior to the onset of reversible complications. At this time, the diagnosis of NAFLD is made with costly radiologic studies and invasive biopsy. These studies are only diagnostic once changes to hepatic tissue have occurred. The diagnosis of NAFLD by traditional methods may not allow for successful intervention and may not be readily available in areas with already sparse medical resources. In this literature review, we identify a list of biomarkers common among CVD, T2DM, obesity, MetS and NAFLD. From this research we propose the following biomarkers are good candidates for inclusion in a panel of biomarkers for the early detection of NAFLD: adiponectin, AST, ALT, apo-B, CK18, CPS1, CRP, FABP-1, ferritin, GGT, GRP78, HDL-C, IGF-1, IL-1β, 6, 8, 10, IRS-2PAI-1, leptin, lumican, MDA SREBP-1c and TNF-α. Creating and implementing a biomarker panel for the early detection and attenuation of NAFLD, prior to the onset of irreversible complication would provide maximum benefit and decrease the disease burden on the patients and healthcare system of WV. 2017-09-29 2017-10 /pmc/articles/PMC5701750/ /pubmed/29177105 http://dx.doi.org/10.4172/2155-9899.1000523 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Sharma, Dana L.
Lakhani, Hari Vishal
Klug, Rebecca L.
Snoad, Brian
El-Hamdani, Rawan
Shapiro, Joseph I.
Sodhi, Komal
Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
title Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
title_full Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
title_fullStr Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
title_full_unstemmed Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
title_short Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
title_sort investigating molecular connections of non-alcoholic fatty liver disease with associated pathological conditions in west virginia for biomarker analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701750/
https://www.ncbi.nlm.nih.gov/pubmed/29177105
http://dx.doi.org/10.4172/2155-9899.1000523
work_keys_str_mv AT sharmadanal investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis
AT lakhaniharivishal investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis
AT klugrebeccal investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis
AT snoadbrian investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis
AT elhamdanirawan investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis
AT shapirojosephi investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis
AT sodhikomal investigatingmolecularconnectionsofnonalcoholicfattyliverdiseasewithassociatedpathologicalconditionsinwestvirginiaforbiomarkeranalysis